Brief: Nicox European Patent Seals ZERVIATE Major Market Coverage To 2030

Nicox SA

05/01/2022 06:39

Jan 5 (Reuters) - NICOX SA  NCOX.PA :
    * NICOX EUROPEAN PATENT SEALS ZERVIATE MAJOR MARKET COVERAGE
TO
2030
    * PATENT COVERAGE FOR ZERVIATE® (CETIRIZINE OPHTHALMIC
SOLUTION),
0.24% IN EUROPE UNTIL 2030
    * PATENT COVERS FORMULATION OF ZERVIATE WHICH IS
COMMERCIALIZED IN
U.S. BY OUR EXCLUSIVE U.S. LICENSEE EYEVANCE PHARMACEUTICALS,
AND ITS USE IN TREATMENT OF SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
OR ALLERGIC RHINOCONJUNCTIVITIS
    * PRESCRIPTION MARKET FOR ALLERGIC CONJUNCTIVITIS PRODUCTS
IN
EUROPE, EASTERN EUROPE AND TURKEY WAS ESTIMATED BY IQVIA AS
AROUND EUR 260 MILLION IN 2020.
    * EUROPEAN PATENT GRANTS EXCLUSIVITY UNTIL 2030, MEANING
THAT
ZERVIATE FORMULATION IS PROTECTED BY GRANTED PATENTS IN U.S. TO
2032, AND IN EUROPE, JAPAN AND CANADA TO 2030
    * ANNOUNCED THAT PATENT EP2408453, COVERING COMPANY'S
PRODUCT
ZERVIATE® (CETIRIZINE OPHTHALMIC SOLUTION), 0.24%, HAS BEEN
ISSUED BY EUROPEAN PATENT OFFICE (EPO).
    * THEEUROPEAN PATENT GRANT MEANS THAT ZERVIATE NOW HAS
PATENT
COVERAGE IN ALL PRINCIPAL PHARMACEUTICAL MARKETSWORLDWIDE.
    * DATA PACKAGE FROM U.S. NEW DRUG APPLICATION FACILITATES
FURTHER
APPROVALS OF ZERVIATE
    * WE ALSO COLLABORATE WITH PARTNERS TO ENSURE ANY NECESSARY
ADDITIONAL REGULATORY DATA ARE GENERATED
    * IN CHINA, WHERE ZERVIATE IS PARTNERED WITH OCUMENSION
THERAPEUTICS, FOR INSTANCE,PIVOTAL PHASE 3 DATA IS BEING
GATHEREDTO SUPPORT LOCAL REGULATORY APPROVAL

Source text for Eikon:  ID:nGNE8kBQ3W 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))